Skip to main content

Elanco Animal Health Inc

For the period ended Sep 30, 2026. Filed Nov 6, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 6, 2026

ELAN$26.76-0.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

Nine Months Ended September 30,
20262025
Cash Flows from Operating Activities
Net income$129$44
Adjustments to reconcile net income to cash flows from operating activities:
Depreciation and amortization520506
Stock-based compensation expense6152
Asset impairment and write-down charges324
Sold portion of royalty and milestone revenue(39)(10)
Interest on liability for sale of future revenue4420
Changes in operating assets and liabilities, net of acquisitions and divestitures(270)(126)
Other non-cash operating activities, net58(58)
Net Cash Provided by Operating Activities506452
Cash Flows from Investing Activities
Net purchases of property and equipment and software(144)(214)
Cash paid for acquisitions, net of cash acquired(76)—
Proceeds from divestitures—9
Other investing activities, net(12)(10)
Net Cash Used for Investing Activities(232)(215)
Cash Flows from Financing Activities
Proceeds from Revolving Credit Facility—125
Repayments of Revolving Credit Facility—(125)
Proceeds from Securitization Facility50125
Repayments of Securitization Facility(50)(125)
Repayments of long-term borrowings(304)(562)
Proceeds from sale of future revenue, net of transaction costs—290
Shares repurchased for employee tax withholdings(36)(14)
Other financing activities, net(15)29
Net Cash Used for Financing Activities(355)(257)
Effect of exchange rate changes on cash and cash equivalents157
Net (decrease) increase in cash and cash equivalents(80)37
Cash and cash equivalents – beginning of period545468
Cash and cash equivalents – end of period$465$505
Supplemental disclosure of non-cash investing and financing activities:
Right-of-use assets obtained in exchange for finance lease liability$—$226
Consideration to be transferred in a business combination$165$—

2026 Q3 Form 10-Q | 8

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.